Reablement strategies targeting sarcopenia

1. Reablement strategies targeting sarcopenia decreases C-terminal agrin fragment in humans (-61.77 at 18 weeks).

   “CAF decreased at 18 weeks (-61.77; p < .001).”

   Human trialOlder adults with sarcopenia in long-term care settings; compared with usual activitiesblood18 weeksn = 78

   Cluster randomized trial of reablement strategies targeting sarcopenia (ReStart-S) in long-term care settings

   The journals of gerontology. Series A, Biological sciences and medical sciences·31 May 2026

More on C-terminal agrin fragment

1. Reablement strategies targeting sarcopenia increases skeletal muscle index in humans (0.20 at 18 weeks).

   “SMI improved at 18 weeks (0.20; p = .011).”

   Human trialOlder adults with sarcopenia in long-term care settings; compared with usual activitiesskeletal muscle18 weeksn = 78

   Cluster randomized trial of reablement strategies targeting sarcopenia (ReStart-S) in long-term care settings

   The journals of gerontology. Series A, Biological sciences and medical sciences·31 May 2026

1. Reablement strategies targeting sarcopenia improves sarQoL in humans.

   “SarQoL improved at all follow-ups (all p < .001).”

   Human trialOlder adults with sarcopenia in long-term care settings; compared with usual activities6, 12, and 18 weeksn = 78

   Cluster randomized trial of reablement strategies targeting sarcopenia (ReStart-S) in long-term care settings

   The journals of gerontology. Series A, Biological sciences and medical sciences·31 May 2026

1. Reablement strategies targeting sarcopenia improves short Physical Performance Battery in humans.

   “SPPB improved at 6, 12, and 18 weeks (all p < .001).”

   Human trialOlder adults with sarcopenia in long-term care settings; compared with usual activities6, 12, and 18 weeksn = 78

   Cluster randomized trial of reablement strategies targeting sarcopenia (ReStart-S) in long-term care settings

   The journals of gerontology. Series A, Biological sciences and medical sciences·31 May 2026

1. Reablement strategies targeting sarcopenia improves handgrip strength in humans (2.14 (95% CI 0.79–3.48) at 18 weeks).

   “Significant group*time interaction was observed for HGS (F = 5.524; p = .001), improving at 12 (2.49; 95% CI, 1.16-3.82; p < .001) and 18 weeks (2.14; 0.79-3.48; p = .002).”

   Human trialOlder adults with sarcopenia in long-term care settings; compared with usual activities18 weeksn = 78

   Cluster randomized trial of reablement strategies targeting sarcopenia (ReStart-S) in long-term care settings

   The journals of gerontology. Series A, Biological sciences and medical sciences·31 May 2026